43.19
price up icon0.47%   0.20
after-market Handel nachbörslich: 43.19
loading
Schlusskurs vom Vortag:
$42.99
Offen:
$42.83
24-Stunden-Volumen:
1.52M
Relative Volume:
1.00
Marktkapitalisierung:
$5.06B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-8.211
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
-4.93%
1M Leistung:
-8.98%
6M Leistung:
-17.48%
1J Leistung:
-38.40%
1-Tages-Spanne:
Value
$41.70
$43.33
1-Wochen-Bereich:
Value
$41.70
$48.43
52-Wochen-Spanne:
Value
$40.53
$75.71

Cytokinetics Inc Stock (CYTK) Company Profile

Name
Firmenname
Cytokinetics Inc
Name
Telefon
(650) 624-3000
Name
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
0
Name
Twitter
@Cytokinetics
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
CYTK's Discussions on Twitter

Vergleichen Sie CYTK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CYTK
Cytokinetics Inc
43.19 5.06B 18.47M -589.53M -399.80M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-07 Eingeleitet Citigroup Buy
2025-01-22 Eingeleitet Stifel Buy
2024-11-08 Eingeleitet RBC Capital Mkts Outperform
2024-08-13 Herabstufung Goldman Buy → Neutral
2024-01-24 Herabstufung UBS Buy → Neutral
2024-01-05 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-11-09 Eingeleitet Goldman Buy
2023-11-07 Eingeleitet B. Riley Securities Buy
2023-08-15 Eingeleitet SVB Securities Outperform
2023-02-17 Eingeleitet BofA Securities Neutral
2022-12-23 Bestätigt Needham Buy
2022-12-20 Eingeleitet Truist Buy
2022-10-11 Eingeleitet UBS Buy
2022-01-28 Eingeleitet Goldman Buy
2021-12-22 Eingeleitet Oppenheimer Outperform
2021-12-10 Eingeleitet JP Morgan Overweight
2021-10-07 Eingeleitet Jefferies Buy
2021-03-12 Eingeleitet Wolfe Research Outperform
2021-02-18 Eingeleitet Barclays Overweight
2021-01-20 Bestätigt H.C. Wainwright Buy
2020-10-29 Eingeleitet Goldman Neutral
2020-07-10 Eingeleitet Raymond James Strong Buy
2020-05-05 Eingeleitet Mizuho Buy
2020-04-09 Hochstufung Morgan Stanley Equal-Weight → Overweight
2018-09-21 Eingeleitet Cantor Fitzgerald Overweight
2018-09-10 Fortgesetzt Morgan Stanley Equal-Weight
2017-11-22 Bestätigt Morgan Stanley Overweight
2017-11-22 Herabstufung Needham Strong Buy → Buy
2017-11-21 Bestätigt H.C. Wainwright Buy
2017-07-31 Eingeleitet Morgan Stanley Overweight
2017-03-08 Eingeleitet Rodman & Renshaw Buy
2017-02-06 Hochstufung Needham Buy → Strong Buy
2016-12-16 Eingeleitet Cantor Fitzgerald Overweight
2016-07-28 Bestätigt Needham Buy
2015-11-10 Bestätigt FBR Capital Outperform
2015-11-09 Bestätigt ROTH Capital Buy
2015-07-24 Bestätigt MLV & Co Buy
2014-12-31 Bestätigt ROTH Capital Buy
2014-11-04 Hochstufung MLV & Co Hold → Buy
2014-04-28 Bestätigt Needham Buy
Alle ansehen

Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten

pulisher
Mar 30, 2025

Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy - Insider Monkey

Mar 30, 2025
pulisher
Mar 29, 2025

Cytokinetics Announces Data From Phase 1 Study of CK-4021586 - Marketscreener.com

Mar 29, 2025
pulisher
Mar 25, 2025

Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? - MSN

Mar 25, 2025
pulisher
Mar 20, 2025

Cytokinetics Launches EARTH-HCM: An Interactive Tool for Understanding Hypertrophic Cardiomyopathy and Improving Access to Care - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community - The Manila Times

Mar 20, 2025
pulisher
Mar 19, 2025

Cytokinetics EVP Malik sells $87,160 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Cytokinetics EVP Malik sells $87,160 in stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics announces inducement grants under Nasdaq listing rule 5635(C)(4) -March 18, 2025 at 04:15 pm EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics Strengthens Workforce: 13 New Hires Secure Strategic Equity Awards - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy on Cytokinetics, $120 target By Investing.com - Investing.com UK

Mar 18, 2025
pulisher
Mar 17, 2025

Cytokinetics Executives Engage in Multiple Stock Transactions - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Incorporated: Aficamten's Differentiated Profile and Market Potential Is Powering Our Hopefulness! - Smartkarma

Mar 17, 2025
pulisher
Mar 17, 2025

UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating -March 17, 2025 at 11:27 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual ... - NRToday.com

Mar 17, 2025
pulisher
Mar 15, 2025

Cytokinetics’ EVP sells $4,500 in stock By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 15, 2025

Cytokinetics EVP Andrew Callos sells $4,500 in stock By Investing.com - Investing.com UK

Mar 15, 2025
pulisher
Mar 14, 2025

Cytokinetics’ EVP sells $4,500 in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 13, 2025

Cytokinetics EVP Callos Andrew sells shares for $1.17 million By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Cytokinetics EVP Callos Andrew sells shares for $1.17 million - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Charles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Cytokinetics at Barclays Healthcare Conference: Strategic Launch Plans By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 11, 2025

Cytokinetics at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 10, 2025

Citi maintains Cytokinetics stock Buy rating, $86 target By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Why Have Cytokinetics Stocks Plummeted? - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics maintains expectation For Differentiated Label & Risk Mitigation Profile for Aficamten if approved By FDA - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics Completes Midcycle Review with FDA for Aficamten - TipRanks

Mar 10, 2025
pulisher
Mar 09, 2025

Robert I. Blum Sells 16,970 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

B. Riley Brokers Reduce Earnings Estimates for Cytokinetics - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Cytokinetics CEO Robert Blum sells shares worth $737,176 - Investing.com India

Mar 08, 2025
pulisher
Mar 08, 2025

Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook - sharewise

Mar 08, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Fady Ibraham sells $356,025 in stock By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Andrew Callos sells $144,565 in stock By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Andrew Callos sells $144,565 in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Fady Ibraham sells $356,025 in stock - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics Executives Engage in Stock Transactions - TradingView

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics CEO Robert Blum sells shares worth $737,176 By Investing.com - Investing.com UK

Mar 07, 2025
pulisher
Mar 07, 2025

Morgan Stanley raises Cytokinetics stock to Overweight, $67 target By Investing.com - Investing.com UK

Mar 07, 2025
pulisher
Mar 07, 2025

What is B. Riley’s Forecast for Cytokinetics Q1 Earnings? - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Cytokinetics assumed with an Overweight at Morgan Stanley - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Cytokinetics Positioned for Growth: Buy Rating Backed by Aficamten’s Market Potential and Upcoming PDUFA Date - TipRanks

Mar 06, 2025

Finanzdaten der Cytokinetics Inc-Aktie (CYTK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Kapitalisierung:     |  Volumen (24h):